Stock Analysis: Raffles Medical Group | Lianhe Zaobao

Raffles Medical Group recommends buying, with a target price of 1.15 yuan and a closing price of 1.00 yuan. It is expected that net profit will increase by 16% year-on-year in the second half of 2025, continuing into 2026 and 2027, achieving double-digit growth. Benefiting from the recovery of local hospital business and improvement in insurance business, the reform of comprehensive health insurance plans will help curb medical cost inflation. Raffles Medical's insurance premiums remain unchanged, providing a competitive advantage. Other catalysts include the improvement of hospital revenue and expenditure balance in China and the advancement of acquisition cases in Vietnam